| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2005 | US20050209135 Etherification of an N-protected-2-carboxyl-4-hydroxypyrrolidine with a 4-halo-quinolone, amidation with a 1-amino-2-vinylcylcopropane, deprotecting the ring nitrogen, amidation with a 7-octenoic acid, ring closing metathesis with 2nd generation Hoveyda's catalyst; one pot process; Hepatitis C viricides |
| 09/22/2005 | US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist |
| 09/22/2005 | US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 09/22/2005 | US20050208568 Providing cell capable of binding azetidinone cholesterol absorption inhibitor; measuring fluorescence; competitive binding assays |
| 09/22/2005 | US20050208528 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 09/22/2005 | US20050208511 DMBT1 as a clinical marker and uses thereof |
| 09/22/2005 | US20050208496 Using enhanced interleukin gene expression as diagnostic indicator of respiratory system disorders |
| 09/22/2005 | US20050208472 Using angiogenesis polypeptide as screening tools iin identifying modulators of for prevention and treatment of cell proliferative disorders; angiogenesis inhibitors |
| 09/22/2005 | US20050208197 Agonists/antagonists of muscarine M3 receptors, obtained from beer through isolation and purification; distillation; chromatography; side effect reduction |
| 09/22/2005 | US20050208162 Esterified fatty acid composition |
| 09/22/2005 | US20050208161 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals |
| 09/22/2005 | US20050208155 New DNA polymerase inhibitors, mikanolide and dihydromikanolide |
| 09/22/2005 | US20050208153 Method of treating acne |
| 09/22/2005 | US20050208152 Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications |
| 09/22/2005 | US20050208151 Treatment of rheumatoid arthritis with FLIP antagonists |
| 09/22/2005 | US20050208150 Compositions for elastrogenesis and connective tissue treatment |
| 09/22/2005 | US20050208147 Isolation of bivittoside D from sea cucumber and activity thereof |
| 09/22/2005 | US20050208146 Novel dosage and administration method for oral camptosar |
| 09/22/2005 | US20050208139 comprising Z isomeric form and E isomeric form of 4-hydroxy tamoxifen; not affected the drug potency; drug mixture in a gel, a solution, patch, in a unit dose packet or in a multiple dose container with a metered pump; new drug form; drug delivery device |
| 09/22/2005 | US20050208138 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent; drug delivery method; sustained releasing the biodrug |
| 09/22/2005 | US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture |
| 09/22/2005 | US20050208135 Monocompartment osmotic controlled drug delivery system |
| 09/22/2005 | US20050208132 Methods and dosage forms for reducing side effects of benzisozazole derivatives |
| 09/22/2005 | US20050208130 Tablet formulations comprising valsartan |
| 09/22/2005 | US20050208129 Prolonged release bioadhesive therapeutic systems |
| 09/22/2005 | US20050208128 Immediate release tablet |
| 09/22/2005 | US20050208127 Comprises D-mannitol having average particle diameter of 31-80 mu m, active ingredient, disintegrant, and stearic acid or metallic stearate in an amount of 0.01-0.5% by weight; rapidly disintegrates in oral cavity; method of external lubricating compression makes porosity small, enables small tablet |
| 09/22/2005 | US20050208125 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances |
| 09/22/2005 | US20050208124 Drugs containing riboflavin-type compounds |
| 09/22/2005 | US20050208123 Vaccine comprising a major outer membrane protein from chlamydia and a mucosal adjuvant such as a combination of QS21 and 3D-MPL, or chlorea toxin or heat labile enterotoxin; provides protection from Chlamydia induced infertility |
| 09/22/2005 | US20050208122 Biodegradable biocompatible implant and method of manufacturing same |
| 09/22/2005 | US20050208119 Preparations of chelating agents encapsulated in micelles or liposomes; comprising alpha lipoic acid and micelles or liposomes containing EDTA or other chelators and magnesium chloride; for transferring antioxidant and chelating agent, across cell membrane; therapy for toxic heavy metal poisoning |
| 09/22/2005 | US20050208118 Preparations of chelating agents encapsulated in micelles or liposomes; comprising alpha lipoic acid and micelles or liposomes containing EDTA or other chelators and magnesium chloride; for transferring antioxidant and chelating agent, across cell membrane |
| 09/22/2005 | US20050208117 Analgesic, non-rate controlled, monolithic, subsaturated patch; sufficient to induce and maintain analgesia in a human for at least three days |
| 09/22/2005 | US20050208116 Active substance is dissolved in both layers, the affinity of first layer for active substance being 1.15-10 times lower than that of second layer; percent saturation of active substance in both layers is same and is less than 100%; device is simple and can provide stable delivery over a long period |
| 09/22/2005 | US20050208105 Compositions, kits, and methods utilizing an added boron source |
| 09/22/2005 | US20050208103 Contacting sclera with a therapeutic or diagnostic agent so as to permit its passage into the choroidal and retinal tissues; no significant systemic absorption or tissue damage; eye disorders |
| 09/22/2005 | US20050208102 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies |
| 09/22/2005 | US20050208095 Implanting a medical device by infiltrating a tissue of a host near the implant with an antifibrotic agent, and/or an antiinfective agent and/or a polymer; prevention of surgical adhesions |
| 09/22/2005 | US20050208094 Bone cement compositions having fiber-reinforcement and/or increased flowability |
| 09/22/2005 | US20050208092 Drug delivery; vascular disease; stents, grafts, anastomotic devices, perivascular wraps, sutures and staples |
| 09/22/2005 | US20050208086 Administration of agents inducing DOPAchrome tautomerase (TRP-2) expression for protecting hair follicle melanocytes |
| 09/22/2005 | US20050208083 Decrease infectivity, morbidity, and/or mortality associated with pathogenic exposure while minimizing microbial resistance, toxicity to the recipient |
| 09/22/2005 | US20050208082 Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| 09/22/2005 | US20050208081 With water miscible solubilizer; phosphodiesterase inhibitors; cardiovascular disorders |
| 09/22/2005 | US20050208079 Glucan-based vaccines |
| 09/22/2005 | US20050208070 From Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata |
| 09/22/2005 | US20050208060 Vaccine composition |
| 09/22/2005 | US20050208052 Screening for agonists/antagonists of interleukins; influenza virus; RNA interference; kits |
| 09/22/2005 | US20050208046 TWEAK receptor |
| 09/22/2005 | US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin |
| 09/22/2005 | US20050208040 Polynucleotides and polypeptides encoded thereby |
| 09/22/2005 | US20050208037 Chemotherapeutic agent anthracycline is doxorubicin, daunomycin; radiotherapeutic agent; adenoviral vector; administered intravenously, intramuscularly, intralesionally, subcutaneously, by aerosol |
| 09/22/2005 | US20050208035 Nutritional composition for treating an immune condition |
| 09/22/2005 | US20050208028 Nutrient Medium for maintaining neural cells in injured nervous system |
| 09/22/2005 | US20050208014 In situ formation of a polymeric cyanoacrylate film containing mixed antibiotics applied as a liquid or gel to the skin surface |
| 09/22/2005 | US20050208012 Composition for treatment of skin, hair and nails |
| 09/22/2005 | US20050208002 Whitening cosmetic composition |
| 09/22/2005 | US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid |
| 09/22/2005 | US20050207998 Sunscreen, cosmetic; caffeine sodium benzoate, caffeine triiodide, citrated caffeine, valeriante of caffeine; skin penetrant enhancer water, alcohol; topical ointment, cream, lotion, paste, gel, spray, aerosol, oil, patch; selectively inducing apoptosis in a cell which has UVB-induced DNA damage |
| 09/22/2005 | US20050207996 Use of osteopontin in dental formulations |
| 09/22/2005 | US20050207991 Aerosols for administering drugs by breathing and filling canisters with compounds like fluticasone propionate |
| 09/22/2005 | US20050207990 Stabilised supersaturated solids of lipophilic drugs |
| 09/22/2005 | US20050207989 High storage stability inhalable compositions |
| 09/22/2005 | US20050207988 Polysaccharides for pulmonary delivery of active agents |
| 09/22/2005 | US20050207987 Mixture of tobramycin in carrier; aerosols; respiratory system disorders; drug delivery |
| 09/22/2005 | US20050207985 dispensers containing a mixture of albuterol and ipratropium bromide, used for inducing bronchodialation or providing relief of bronchospasm in in an individual suffering from copd |
| 09/22/2005 | US20050207984 Physical and chemical stability; homogeneity; particle size range; asthma, chronic obstructive pulmonary disease; 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane used as propellants |
| 09/22/2005 | US20050207976 High energy phototherapeutic agents |
| 09/22/2005 | US20050207973 Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy chromans |
| 09/22/2005 | US20050206023 formation of particles of a target substance, such as a pharmaceutical, using a supercritical or near-critical fluid as an anti-solvent |
| 09/22/2005 | US20050205086 Retinoid immunomodulating kit and composition and uses thereof |
| 09/22/2005 | US20050205083 Medicament storage and delivery devices |
| 09/22/2005 | DE20321052U1 Transdermal therapeutic system for delivery of fentanyl, to treat severe and/or chronic pain, including drug-containing adhesive matrix of specific basic acrylate copolymer requiring no penetration accelerators |
| 09/22/2005 | DE102004011512A1 Pharmazeutische Zubereitung enthaltend Pimobendan Pharmaceutical composition comprising pimobendan |
| 09/22/2005 | DE102004010254A1 New 4-heterocyclyl-1-acyl-piperidine derivatives, useful e.g. for treating headache, diabetes and cardiovascular disease, are antagonists of calcitonin-gene related peptide |
| 09/22/2005 | DE102004009153A1 Use of ascorbic acid and/or its derivatives for increasing microcirculation and nutrient supply in skin includes use in cosmetics and dermatics, e.g. emulsion or mousse for skin or face, day or night cream or lotion |
| 09/22/2005 | DE102004009150A1 Use of ascorbic acid and/or its derivatives for cleansing and/or reducing size of skin pores includes use in cosmetics and dermatics, e.g. emulsion or mousse for skin or face, day or night cream or lotion |
| 09/22/2005 | DE10152351B4 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat Solid pharmaceutical formulation for a Piperazinharnstoffderivat |
| 09/22/2005 | DE10100772B4 Ether- und Amidverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidiabetika Ether and amide compounds, processes for their preparation and their use as antidiabetic agents |
| 09/22/2005 | CA2787978A1 Interferon-beta for anti-virus therapy for respiratory diseases |
| 09/22/2005 | CA2601278A1 Prevention of retinopathy by inhibition of the visual cycle |
| 09/22/2005 | CA2563739A1 Bioavailable solid dosage forms of metaxalone |
| 09/22/2005 | CA2560200A1 Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| 09/22/2005 | CA2560176A1 Occlusive biomedical devices, punctum plugs, and methods of use thereof |
| 09/22/2005 | CA2560111A1 Aminophenylpropanoic acid derivative |
| 09/22/2005 | CA2560098A1 2-aminoquinazoline derivative |
| 09/22/2005 | CA2560080A1 Solifenacin-containing composition |
| 09/22/2005 | CA2560079A1 Process for producing medicine |
| 09/22/2005 | CA2560046A1 Methods for suppressing tumor proliferation |
| 09/22/2005 | CA2559826A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
| 09/22/2005 | CA2559802A1 Method for stimulating the immune, inflammatory or neuroprotective response |
| 09/22/2005 | CA2559614A1 Andrographolide and analogues as inhibitors of tnf.alpha. and il-1.beta.expression |
| 09/22/2005 | CA2559560A1 Antiviral composition comprising p-menthane-3, 8-diol |
| 09/22/2005 | CA2559507A1 Compounds, compositions and methods for inhibiting or treating hiv-1 |
| 09/22/2005 | CA2559493A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
| 09/22/2005 | CA2559487A1 Combination of deramciclane and opoids as analgesics |
| 09/22/2005 | CA2559444A1 Imidazopyridazine diones, the production thereof, and the use of the same as a medicament |
| 09/22/2005 | CA2559377A1 Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
| 09/22/2005 | CA2559333A1 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof |